Panitumumab for the Treatment of Metastatic Colorectal Cancer
نویسندگان
چکیده
Béla Pikó1, Ali Bassam1, Enikő Török2, Henriette Ócsai3 and Farkas Sükösd4 1Kálmán Pándy Hospital of the Local Government of Békés County, County, Center of Oncology, Gyula, 2Kálmán Pándy Hospital of the Local Government of Békés County, County Department of Radiology, Gyula, 3Kálmán Pándy Hospital of the Local Government of Békés County, Dermato-Oncology Outpatient Clinic, Gyula, 4University of Szeged, Albert Szent-Györgyi Clinical Center, Department of Pathology, Szeged, Hungary
منابع مشابه
Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care
INTRODUCTION Colorectal cancer is the fourth most common malignant disease. Of newly diagnosed patients, 40% have metastatic disease at diagnosis, and approximately 25% of patients with localized disease at diagnosis will ultimately develop metastatic disease. The benefits of systemic chemotherapy in the treatment of metastatic colorectal cancer over best supportive care have been established. ...
متن کاملA Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer
Metastatic colorectal cancer is the fourth most common cause of death due to cancer after those of lung, stomach, and liver. Anti epidermal growth factor receptor drugs as a targeting therapy seem to be good candidates for curing metastatic colorectal cancer. Two available anti epidermal growth factor receptor monoclonal antibodies are cetuximab and panitumumab which have been approved for meta...
متن کاملTreatment of metastatic colorectal cancer: focus on panitumumab
Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with efficacy in mCRC as monotherapy and in combination with chemotherapy. Kirsten rat sarcoma (KRAS) mutation status has emerged as an important ...
متن کاملEffective panitumumab treatment in patients with heavily pre-treated metastatic colorectal cancer: a case series.
In heavily pre-treated patients with metastatic colorectal cancer (mCRC), further chemotherapy has not demonstrated efficacy. Panitumumab is indicated as monotherapy treatment of epidermal growth factor receptor (EGFR)-expressing, Kirsten (K)-RAS wild-type metastatic colorectal cancer after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-containing regimens. However, panitumumab has n...
متن کاملPanitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
Panitumumab is the first fully human monoclonal antibody to Epidermal Growth Factor Receptor (EGFR) to enter clinical trials for the treatment of solid tumors. The anti-tumor activity of panitumumab has been tested in vitro and in vivo, and inhibition of tumor growth has been observed in numerous cancer models, particularly lung, kidney and colorectal (CRC). Preclinical and clinical studies hav...
متن کاملLong-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma – A Report of Two Cases
BACKGROUND: Second as well as higher-line therapies have a significant influence on progression-free and overall survival of metastatic colorectal cancer patients. However, treatment of late-stage disease remains suboptimal. Therefore, the introduction of new, effective and well-tolerated agents is of major importance. Case Reports: Here we describe the cases of 2 patients with metastatic KRAS ...
متن کامل